Skip to Main Content

Paper Details

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Nat Med
344
2021
Akkermansia, Ipilimumab, NSCLC, Ruminococcus, effector memory T cells, effector, tissue-resident memory and, ipilimumab, metastatic non-small cell lung cancer, nivolumab, non-small cell lung cancer, patients, tumor, tumor immune infiltrates
Author NameAffiliation
Jianjun ZhangUniversity of Texas MD Anderson Cancer Center
Charles LuUniversity of Texas MD Anderson Cancer Center
Phillip A FutrealUniversity of Texas MD Anderson Cancer Center
Jennifer A WargoUniversity of Texas MD Anderson Cancer Center
  • 1 - 4

Datasets

Release 1.2